ODAC To Assess Safety Of Lilly’s Evista As Breast Cancer Preventative
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking advice from its Oncologic Drugs Advisory Committee on expectations for efficacy and risk when dealing with a drug to prevent breast cancer.
You may also be interested in...
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.
Lilly Will Add 40% Capacity To Diabetes Sales Force In Q1
Firm also announces the submission of an sNDA for Evista for breast cancer risk reduction.